Acute upper gastrointestinal bleeding: management
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/cg141
- 1.1 Risk assessment
- 1.2 Resuscitation and initial management
- 1.3 Timing of endoscopy
- 1.4 Management of non-variceal bleeding
- 1.5 Management of variceal bleeding
- 1.6 Control of bleeding and prevention of re-bleeding in patients on NSAIDs, aspirin or clopidogrel
- 1.7 Primary prophylaxis for acutely ill patients in critical care
- 1.8 Information and support for patients and carers
The following guidance is based on the best available evidence. The full guideline gives details of the methods and the evidence used to develop the guidance.
1.1.1 Use the following formal risk assessment scores for all patients with acute upper gastrointestinal bleeding:
the Blatchford score at first assessment, and
the full Rockall score after endoscopy.
1.1.2 Consider early discharge for patients with a pre-endoscopy Blatchford score of 0.
1.2.1 Transfuse patients with massive bleeding with blood, platelets and clotting factors in line with local protocols for managing massive bleeding.
1.2.2 Base decisions on blood transfusion on the full clinical picture, recognising that over-transfusion may be as damaging as under-transfusion.
1.2.3 Do not offer platelet transfusion to patients who are not actively bleeding and are haemodynamically stable.
1.2.4 Offer platelet transfusion to patients who are actively bleeding and have a platelet count of less than 50 x 109/litre.
1.2.5 Offer fresh frozen plasma to patients who are actively bleeding and have a prothrombin time (or international normalised ratio) or activated partial thromboplastin time greater than 1.5 times normal. If a patient's fibrinogen level remains less than 1.5 g/litre despite fresh frozen plasma use, offer cryoprecipitate as well.
1.2.6 Offer prothrombin complex concentrate to patients who are taking warfarin and actively bleeding.
1.2.7 Treat patients who are taking warfarin and whose upper gastrointestinal bleeding has stopped in line with local warfarin protocols.
1.2.8 Do not use recombinant factor Vlla except when all other methods have failed.
1.3.1 Offer endoscopy to unstable patients with severe acute upper gastrointestinal bleeding immediately after resuscitation.
1.3.2 Offer endoscopy within 24 hours of admission to all other patients with upper gastrointestinal bleeding.
1.3.3 Units seeing more than 330 cases a year should offer daily endoscopy lists. Units seeing fewer than 330 cases a year should arrange their service according to local circumstances.
1.4.1 Do not use adrenaline as monotherapy for the endoscopic treatment of non-variceal upper gastrointestinal bleeding.
1.4.2 For the endoscopic treatment of non-variceal upper gastrointestinal bleeding, use one of the following:
a mechanical method (for example, clips) with or without adrenaline
thermal coagulation with adrenaline
fibrin or thrombin with adrenaline.
1.4.3 Do not offer acid-suppression drugs (proton pump inhibitors or H2-receptor antagonists) before endoscopy to patients with suspected non-variceal upper gastrointestinal bleeding.
1.4.4 Offer proton pump inhibitors to patients with non-variceal upper gastrointestinal bleeding and stigmata of recent haemorrhage shown at endoscopy.
1.4.5 Consider a repeat endoscopy, with treatment as appropriate, for all patients at high risk of re-bleeding, particularly if there is doubt about adequate haemostasis at the first endoscopy.
1.4.6 Offer a repeat endoscopy to patients who re-bleed with a view to further endoscopic treatment or emergency surgery.
1.4.7 Offer interventional radiology to unstable patients who re-bleed after endoscopic treatment. Refer urgently for surgery if interventional radiology is not promptly available.
1.5.1 Offer terlipressin to patients with suspected variceal bleeding at presentation. Stop treatment after definitive haemostasis has been achieved, or after 5 days, unless there is another indication for its use.
1.5.2 Offer prophylactic antibiotic therapy at presentation to patients with suspected or confirmed variceal bleeding.
1.5.3 Use band ligation in patients with upper gastrointestinal bleeding from oesophageal varices.
1.5.4 Consider transjugular intrahepatic portosystemic shunts (TIPS) if bleeding from oesophageal varices is not controlled by band ligation.
1.6.1 Continue low-dose aspirin for secondary prevention of vascular events in patients with upper gastrointestinal bleeding in whom haemostasis has been achieved.
1.6.2 Stop other non-steroidal anti-inflammatory drugs (including cyclooxygenase-2 [COX-2] inhibitors) during the acute phase in patients presenting with upper gastrointestinal bleeding.
1.6.3 Discuss the risks and benefits of continuing clopidogrel (or any other thienopyridine antiplatelet agents) in patients with upper gastrointestinal bleeding with the appropriate specialist (for example, a cardiologist or a stroke specialist) and with the patient.
1.7.1 Offer acid-suppression therapy (H2-receptor antagonists or proton pump inhibitors) for primary prevention of upper gastrointestinal bleeding in acutely ill patients admitted to critical care. If possible, use the oral form of the drug.
1.7.2 Review the ongoing need for acid-suppression drugs for primary prevention of upper gastrointestinal bleeding in acutely ill patients when they recover or are discharged from critical care.
1.8.1 Establish good communication between clinical staff and patients and their family and carers at the time of presentation, throughout their time in hospital and following discharge. This should include:
giving verbal information that is recorded in medical records
different members of clinical teams providing consistent information
providing written information where appropriate
ensuring patients and their families and carers receive consistent information.
 At the time of publication (June 2012), terlipressin was indicated for the treatment of bleeding from oesophageal varices, with a maximum duration of treatment of 72 hours (3 days). Prescribers should consult the relevant summary of product characteristics. Informed consent for off-label use of terlipressin should be obtained and documented.